DE VOS PHARMA
ActiveSummary
DE VOS PHARMA has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €866,025 and a net result of €92,384. Equity is growing by about 5.2% per year across the filed financial years. Its solvency ranks better than 57% of 12,724 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
30-10
Gazette deed
Resignation: DGI CONSULTING (niet statutaire zaakvoerder)Reappointment: DGI CONSULTING (director) · Capital conversion · Reserve release13 facts ▸
- General meeting, 25-10-2023
- Other provision, “aanpassing statuten aan WVV en behoud rechtsvorm BV, statuten aanpassen aan bepalingen van het Wetboek van vennootschappen en verenigingen” (deed in Dutch)
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Reserve release, “beschikbaar voor uitkering, artikel 39, §2, derde lid van de wet van 23-03-2019 tot invoering van het Wetboek van vennootschappen en verenigingen en houdende…” (deed in Dutch)
- Purpose change
- Amendment of the articles
- Capital
- Director in office, DE VOS Ilse
- Director resignation, DGI CONSULTING (niet statutaire zaakvoerder)
- Director reappointment, DGI CONSULTING (director (not named in the articles))
- Power of attorney
- Power of attorney, Herbert HOUBEN
- +1 further fact in this act
About the unread acts
Of the 5 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 4 have not been read yet: what they contain is neither established nor disproved here.